The vaccine stimulates innate sensing (including via TLR7) to induce type I IFN and dendritic cell activation, priming HPV16 E6/E7–specific CD8+ T cells that kill HPV16-positive tumor cells via MHC I recognition; TLR7-expressing cells are not targeted for cytotoxic killing.